Home The Word Brain My Amedeo FAQ Privacy About   


Chinese Coaching

Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.


  Pulmonary Hypertension, December 2025

Free Subscription


Abstracts

Retrieve all available abstracts of the following 142 articles:
HTML format


 

Single Articles

  1. CHEN D, Lin D, Zhang L, Zhang X, et al
    Targeted Drugs, PADN, and Transcatheter Closure for Atrial Septal Defect-Associated Pulmonary Hypertension.
    JACC Case Rep. 2025 Nov 28:106116. doi: 10.1016/j.jaccas.2025.106116.
    PubMed    
    Abstract available

  2. CHEN X, Jilaihawi H, Wang Y
    One-stop pulmonary artery denervation and transcatheter tricuspid annuloplasty in combined pre- and post-capillary pulmonary hypertension with severe tricuspid regurgitation.
    Eur Heart J. 2025 Nov 28:ehaf934. doi: 10.1093.
    PubMed    


  3. BANASZKIEWICZ M, Szwed P, Darocha S, Kurzyna P, et al
    Efficacy of balloon pulmonary angioplasty in the treatment of chronic thromboembolic pulmonary hypertension in patients with cancer comorbidity.
    Kardiol Pol. 2025 Nov 28. doi: 10.33963/v.phj.109876.
    PubMed    


  4. ASLAMZAI M, Hakimi T, Mukhlis AH, Mansoori EA, et al
    Very rare combination of Pierre Robin sequence with patent ductus arteriosus, severe persistent pulmonary hypertension, and sepsis in an Afghan neonate: a case report and literature review.
    Oxf Med Case Reports. 2025;2025:omaf235.
    PubMed    
    Abstract available

  5. DENG X, Wang J, Xiong M, Wang T, et al
    [Silencing DDX17 inhibits proliferation and migration of pulmonary arterial smooth muscle cells in vitro by decreasing mTORC1 activity].
    Nan Fang Yi Ke Da Xue Xue Bao. 2025;45:2475-2482.
    PubMed    
    Abstract available

  6. LI M, Jin Q, Pan W, Tian D, et al
    Serum Proteomic Profiling Uncovers LGALS3BP as a Potential Biomarker for Idiopathic Pulmonary Arterial Hypertension.
    Clin Respir J. 2025;19:e70138.
    PubMed    
    Abstract available

  7. YANG F, Yan Y, Jiang W, Wang Z, et al
    Correction: Impaired right atrial function preceding right ventricular systolic dysfunction: clinical utility and long-term prognostic value in pulmonary hypertension.
    Insights Imaging. 2025;16:264.
    PubMed    


  8. STYCZEN A, Krysa M, Mertowska P, Grywalska E, et al
    The Role of Toll-like Receptors and Viral Infections in the Pathogenesis and Progression of Pulmonary Arterial Hypertension-A Narrative Review.
    Int J Mol Sci. 2025;26:11143.
    PubMed    
    Abstract available

  9. IANCU DG, Mares RG, Cristescu L, Suteu RA, et al
    Inflammation-Based Hematologic Indices as Prognostic Markers in Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension: A Hypothesis-Generating Registry Study.
    Int J Mol Sci. 2025;26:10940.
    PubMed    
    Abstract available

  10. HEBERT A, Villeneuve A, Lapointe A, Drolet C, et al
    Targeted Neonatal Echocardiography in Bronchopulmonary Dysplasia: A Framework for Screening and Management of Chronic Pulmonary Hypertension.
    J Clin Med. 2025;14:8161.
    PubMed    
    Abstract available

  11. ZHAO L
    Microbiome Dysregulation and Inflammation: Key Players in Pulmonary Hypertension Pathophysiology.
    Biomedicines. 2025;13:2750.
    PubMed    
    Abstract available

  12. BERECZKY Z, Kolodzey G, Borsos S, Balogh L, et al
    Genetic Analysis of Patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH): A Single-Center Observational Study.
    Genes (Basel). 2025;16:1336.
    PubMed    
    Abstract available

  13. KRIZNAR T, Grosek S, Perme T
    The Incidence of Pulmonary Hypertension and the Association with Bronchopulmonary Dysplasia in Preterm Infants of Extremely Low Gestational Age: Single Centre Study at the Maternity Hospital of University Medical Centre Ljubljana, Slovenia.
    Children (Basel). 2025;12:1441.
    PubMed    
    Abstract available

  14. YADETA D, Bekele A, Bayisa T, Adem A, et al
    Clinical characteristics and causes of non-cardiac pulmonary hypertension in two major tertiary teaching hospitals in Ethiopia: a cross-sectional descriptive study.
    BMC Res Notes. 2025;18:496.
    PubMed    
    Abstract available

  15. XUN Q, Yang Q, Zhu G, Wang W, et al
    Cullin 2 elevates Warburg effect to accelerate the development of hypoxic pulmonary hypertension.
    Am J Pathol. 2025 Nov 24:S0002-9440(25)00428.
    PubMed    
    Abstract available

  16. WANG D, Huang N, Cai M, Huang R, et al
    Nitazoxanide reverses pulmonary vascular remodeling in pulmonary hypertension by targeting the IMPA1-RAGE signaling axis.
    Toxicol Appl Pharmacol. 2025 Nov 24:117657. doi: 10.1016/j.taap.2025.117657.
    PubMed    
    Abstract available

  17. PAEZ-CARPIO A, Serrano E, Domenech-Ximenos B, Cornellas L, et al
    Dual-energy computed tomography (CT) versus cone-beam computed tomography (CT) in chronic thromboembolic pulmonary hypertension: diagnostic accuracy compared with digital subtraction angiography.
    Clin Radiol. 2025;92:107152.
    PubMed    
    Abstract available

  18. SAMIEIRAD S, Amini M, Raji H, Sadeghi FH, et al
    Prevalence and characteristics of pulmonary hypertension in obstructive sleep apnea: a systematic review and meta-analysis.
    Sleep Breath. 2025;29:367.
    PubMed    
    Abstract available

  19. PHIMISTER A, Handler S, Dasgupta M, Pan A, et al
    Hospitalizations and outcomes in extremely premature infants with bronchopulmonary dysplasia and pulmonary hypertension at 5 years.
    Eur J Pediatr. 2025;184:796.
    PubMed    
    Abstract available

  20. AL-WSABI N, Al-Ganadi AA, Kadry MA, Noman T, et al
    Impact of pulmonary hypertension on early outcomes of valve surgery in rheumatic heart disease: The first outcome-based study from Yemen.
    Asian Cardiovasc Thorac Ann. 2025 Nov 26:2184923251399732.
    PubMed    
    Abstract available

  21. PENG W, Bai W, Lyu X, Xu X, et al
    Altitude-Related Differences in Biventricular Remodeling and the Clinical Profile of Pulmonary Hypertension: An Exploratory Cardiovascular Magnetic Resonance Study.
    J Am Heart Assoc. 2025 Nov 26:e041036. doi: 10.1161/JAHA.125.041036.
    PubMed    
    Abstract available

  22. LYAPINA IN, Martynyuk TV, Bogdanov LA, Stasev AN, et al
    Histological Analysis of Lung Tissue and Pulmonary Vessels in Cardiac Surgery Patients with Mitral Valve Disease and Pulmonary Hypertension.
    Kardiologiia. 2025;65:59-70.
    PubMed    
    Abstract available

  23. WELLER H, Hickmann A, Heiter J, Klinkenberg D, et al
    [Alveolar capillary dysplasia with FOXF1 mutation as differential diagnosis in refractory persistent pulmonary hypertension (PPHN)].
    Klin Padiatr. 2025 Nov 24. doi: 10.1055/a-2710-7277.
    PubMed    


  24. ZHANG Y, Chen W, Yang K, Hao T, et al
    Glycolysis inhibition and AMPK activation: a critical role of CTRP1 deficiency in the treatment of hypoxia-induced pulmonary hypertension.
    Exp Cell Res. 2025;454:114838.
    PubMed    
    Abstract available

  25. NAJJAR RS, Jagirdar J, Gewirtz AT
    A Plant-Based Diet Alleviates Molecular Pulmonary Abnormalities in Hypertension.
    Adv Respir Med. 2025;93:49.
    PubMed    
    Abstract available

  26. FOSTER B, Khan S, Suarez Gonzalez A, Gillenwater S, et al
    Pulmonary Veno-Occlusive Disease: A Comprehensive Review of Diagnostic Challenges, Therapeutic Limitations, and Evolving Management.
    Adv Respir Med. 2025;93:48.
    PubMed    
    Abstract available

  27. WASILEWSKA E, Dera N, Minarowski L, Osinski L, et al
    Can Milrinone Be a Therapeutic Alternative in Persistent Pulmonary Hypertension of the Newborn? A Case Series and Narrative Review.
    Pediatr Rep. 2025;17:116.
    PubMed    
    Abstract available

  28. AVITABILE CM, Chen PW, Faig W, Zemel B, et al
    Physical activity traits from wrist sensors correlate with clinical status in pediatric pulmonary hypertension.
    medRxiv [Preprint]. 2025 Oct 28:2025.10.26.25338733.
    PubMed    
    Abstract available

  29. POOR HD, Zhang J, Hannah-Clark S, Saini S, et al
    Sotatercept Improves Small Airway Disease and Hyperinflation in Patients with Pulmonary Hypertension.
    medRxiv [Preprint]. 2025 Oct 9:2025.10.08.25337393.
    PubMed    
    Abstract available

  30. POOR HD, Eisenberg E, Saini S, Hannah-Clark S, et al
    Sotatercept is Associated with Improved Lung Function in Sarcoidosis-Associated Pulmonary Hypertension.
    medRxiv [Preprint]. 2025 Oct 8:2025.10.03.25337126.
    PubMed    
    Abstract available

  31. BHATTACHARYYA P, Sengupta S, Paul M, Saha D, et al
    Appreciation of Increased Pulmonary Vascular Resistance from the Maximum Desaturation in 2-Chair Test: An Appraisal.
    Int J Chron Obstruct Pulmon Dis. 2025;20:3725-3735.
    PubMed    
    Abstract available

  32. YANG Q, Chen P, He X, Jian J, et al
    Melk facilitates pulmonary artery smooth muscle cell proliferation and migration in pulmonary hypertension via modulation of YAP/TAZ signaling.
    Front Cell Dev Biol. 2025;13:1693346.
    PubMed    
    Abstract available

  33. CAI Z, Qi X, Zhou D, Dai H, et al
    COMPERA 2.0 risk stratification in patients with severe aortic stenosis: implication for group 2 pulmonary hypertension.
    J Zhejiang Univ Sci B. 2025;26:1076-1085.
    PubMed    
    Abstract available

  34. CHEN Y, Lv Y, Yang M, Qian Z, et al
    The P4HA1/HIF1alpha feedback loop modulates endothelial dysfunction in pulmonary hypertension.
    Respir Res. 2025 Nov 22. doi: 10.1186/s12931-025-03419.
    PubMed    
    Abstract available

  35. LEE SS, Moon JH, Lee SH
    The AOPP-cNOS relay: A Redox-Metabolic pathway in the lung-brain axis of pulmonary hypertension and neurovascular injury.
    Free Radic Biol Med. 2025;243:367-380.
    PubMed    
    Abstract available

  36. AZHAR M, Majdpour DL, Mesa SE, Rubens MB, et al
    Hospital outcomes of interstitial lung disease with pulmonary hypertension patients versus pulmonary hypertension alone: results from the national inpatient sample (2016-2021).
    Heart Lung. 2025;76:55-59.
    PubMed    
    Abstract available

  37. OZTURK O, Aslankoc R, Saygin M, Ozmen O, et al
    Apelin-13 Attenuates Right Ventricular Hypertrophy and Pulmonary Fibrosis in a Monocrotaline Model of Pulmonary Hypertension.
    Clin Exp Pharmacol Physiol. 2026;53:e70094.
    PubMed    
    Abstract available

  38. TURAN B, Kocakaya D, Yildizeli SO, Akaslan D, et al
    The relationship between preoperative clinical, respiratory, and hemodynamic parameters and the surgical anatomical classification of thrombi in patients with chronic thromboembolic pulmonary hypertension.
    BMC Pulm Med. 2025;25:540.
    PubMed    
    Abstract available

  39. ZHAO X, Yin J, Lu T, Chen H, et al
    ALOX15/15B regulating autophagy to promote pulmonary arterial hypertension via PI3K/AKT/mTOR pathway.
    Eur J Pharmacol. 2025 Nov 7:178338. doi: 10.1016/j.ejphar.2025.178338.
    PubMed    
    Abstract available

  40. MOUSAVINEJAD SN, Lachouri R, Bahadorzadeh M, Khatami SH, et al
    Artificial intelligence for arterial blood gas interpretation.
    Clin Chim Acta. 2026;579:120691.
    PubMed    
    Abstract available

  41. XING C, Limei L, Liping X, Lixiang L, et al
    Mechanistic study of ANXA3-mediated endoplasmic reticulum stress promoting M1 macrophage polarization in pulmonary arterial hypertension based on bioinformatics and nine machine learning algorithms.
    Comput Biol Med. 2025;198.
    PubMed    
    Abstract available

  42. KRIS LP, Dixon DL, Bihari S, Carr JM, et al
    Revisiting the monocrotaline-treated rat as a model of inflammatory lung disease: COVID-19 and future pandemic threats?
    Animal Model Exp Med. 2025;8:1785-1793.
    PubMed    
    Abstract available

  43. DA SILVA BEDIN AM, Janning JA, Jose Tondo V, Galan V, et al
    Tartaric acid pellets as a core for extended release of sildenafil citrate: development via solid dispersion and factorial design.
    Drug Dev Ind Pharm. 2025;51:1828-1842.
    PubMed    
    Abstract available

  44. HSIEH CC, Kuo HF, Wang HH, Hua MD, et al
    Plumbagin improves pulmonary vascular remodeling in PAH via miR-21-5p/MMP/TIMP regulation, with diagnostic implications for cardiac function.
    Biomed Pharmacother. 2025;192:118604.
    PubMed    
    Abstract available

  45. FELOUKIDIS C, Kosmidis D, Arvanitaki A, Anastasiou V, et al
    Echocardiographic right-ventricular global wasted work predicts haemodynamics and risk profile in pulmonary arterial hypertension.
    Eur Heart J Cardiovasc Imaging. 2025;26:1855-1863.
    PubMed    
    Abstract available

  46. FREIRE TC, Nascimento-Filho AV, Ferreira MS, da Silva Dias D, et al
    Impact of combined exercise training in peripheral and diaphragm muscles and in mortality in a preclinical model of pulmonary arterial hypertension.
    Pflugers Arch. 2025;477.
    PubMed    
    Abstract available

  47. YOSHIDA T, Matsuura K, Uemura A, Tanaka R, et al
    Changes in hemodynamics of pulmonary artery using Flowire in a canine model of acute pulmonary thromboembolism.
    Animal Model Exp Med. 2025;8:1888-1895.
    PubMed    
    Abstract available

  48. COSTA SFF, Soares LL, Leite LB, Portes AMO, et al
    Skeletal muscle atrophy in pulmonary arterial hypertension: potential mechanisms and effects of physical exercise.
    Heart Fail Rev. 2025;30:1191-1205.
    PubMed    
    Abstract available

  49. FEMLING JK, Figueiredo PS, Reilly AJ, Williams JD, et al
    Does Prior Respiratory Infection Increase the Risk of High-Altitude Pulmonary and Cerebral Edema? A Case Report.
    High Alt Med Biol. 2025;26:411-415.
    PubMed    
    Abstract available

  50. GODINO C, Sisinni A, Raone L, Sparasci FM, et al
    Hemodynamic Right Heart Catheterization Before Transcatheter Mitral and Tricuspid Therapies.
    Circ Heart Fail. 2025;18:e012489.
    PubMed    
    Abstract available

  51. SHECHTER A, Gupta A, Kaewkes D, Taheri H, et al
    Mitral transcatheter edge-to-edge repair in patients with severe pulmonary hypertension.
    Clin Res Cardiol. 2025 Dec 4. doi: 10.1007/s00392-025-02796.
    PubMed    
    Abstract available

  52. LI L, Wang H, Chen Y, Tan X, et al
    Global burden of pulmonary arterial hypertension and health inequality in women of childbearing age from 1990 to 2021, with projections up to 2040: the global burden of disease 2021 study.
    Front Public Health. 2025;13:1700855.
    PubMed    
    Abstract available

  53. GRIFFITHS M
    Beyond Resistance: Pulmonary Vascular Compromise as a Mechanistic Window Into Pediatric Pulmonary Hypertension.
    Pulm Circ. 2025;15:e70218.
    PubMed    


  54. NAMBIAR VEETIL N, Gransar T, Liu SF, Almalla A, et al
    Remodelling of the endothelial extracellular matrix promotes smooth muscle cell hyperplasia in pulmonary hypertension due to left heart disease.
    Cardiovasc Res. 2025 Dec 3:cvaf238. doi: 10.1093.
    PubMed    
    Abstract available

  55. REDDY YNV, Frantz RP, Hemnes AR, Hassoun PM, et al
    Prevalence and Clinical Implications of Excess Adiposity in Group 1 Pulmonary Hypertension.
    Circ Heart Fail. 2025 Dec 3:e013591. doi: 10.1161/CIRCHEARTFAILURE.125.013591.
    PubMed    
    Abstract available

  56. WU LW, Chen M, Jiang CY, Jiang DJ, et al
    Inactivation of AXL in Cardiac Fibroblasts Alleviates Right Ventricular Remodeling in Pulmonary Hypertension.
    Adv Sci (Weinh). 2025 Dec 3:e08995. doi: 10.1002/advs.202508995.
    PubMed    
    Abstract available

  57. WANG Y, Li X, Huang Z, Duan A, et al
    Impact of Stress Hyperglycemia Ratio on Adverse Outcomes in Patients With Chronic Thromboembolic Pulmonary Hypertension.
    Clin Transl Sci. 2025;18:e70426.
    PubMed    
    Abstract available

  58. PAPA S, D'Alto M, Scelsi L, Acquaro M, et al
    ASPYRE-1 study: An Italian multicenter prospective study on pulmonary hypertension modality of death and validation of reveal risk score.
    Vascul Pharmacol. 2025 Nov 29:107561. doi: 10.1016/j.vph.2025.107561.
    PubMed    
    Abstract available

  59. NAING P, Scalia GM, Murdoch D, Ranasinghe I, et al
    Artificial intelligence enhanced contemporary pulmonary hypertension care.
    Am Heart J Plus. 2025;60:100673.
    PubMed    
    Abstract available

  60. SI M, Hu Y, Jin Z, Mao Y, et al
    NF-kappaB and pulmonary hypertension: Advances in mechanistic research and therapeutic applications.
    Am Heart J Plus. 2025;60:100669.
    PubMed    
    Abstract available

  61. ARUNACHALAM A, Guasch FM, Nayak T, John M, et al
    Pulmonary Arterial Wedge Oxygen Saturation: Does It Confirm Wedge Position in Patients With Pulmonary Hypertension?
    Pulm Circ. 2025;15:e70214.
    PubMed    
    Abstract available

  62. TANNENBERG P, Tran-Lundmark K, Chang YT, Gladh H, et al
    Exploring the Impact of Platelet-Derived Growth Factor D in Pulmonary Hypertension Development.
    Pulm Circ. 2025;15:e70216.
    PubMed    
    Abstract available

  63. YAMASHITA M, Saiki H, Saito K, Sato A, et al
    Volume Loading May Compromise Left Ventricular Filling in Patients with a Borderline Hypoplastic Left Ventricle.
    Int Heart J. 2025;66:1019-1024.
    PubMed    
    Abstract available

  64. DIGNAM JP, Sharma S, Aitchison G, Gebril A, et al
    Cytochrome P450 1A1 influences obesity-induced pulmonary hypertension.
    Br J Pharmacol. 2025 Nov 30. doi: 10.1111/bph.70244.
    PubMed    
    Abstract available

  65. KOLODZEY G, Balogh L, Barta J, Peter A, et al
    [Chronic thromboembolic pulmonary hypertension - the hidden disease].
    Orv Hetil. 2025;166:1908-1915.
    PubMed    
    Abstract available

  66. BASHIR A, Rizwan MA, Bashir M
    A Machine Learning-Based Model to Estimate the Risk of Pulmonary Hypertension in Chronic Kidney Disease Patients.
    J Clin Hypertens (Greenwich). 2025;27:e70190.
    PubMed    


  67. CHEN N, Yin X, Wang D, Zhou D, et al
    Downregulation of KLF2 impairs pulmonary endothelial function and promotes persistent pulmonary hypertension of the newborn.
    Biochem Pharmacol. 2025 Nov 27:117572. doi: 10.1016/j.bcp.2025.117572.
    PubMed    
    Abstract available

  68. LU G, Sun H, Xu M, Fu C, et al
    Asiaticoside alleviates hypoxic pulmonary hypertension by regulating the voltage-gated potassium channel 1.5 through the protein tyrosine phosphatase non-receptor type 7 pathway.
    Phytomedicine. 2025;150:157595.
    PubMed    
    Abstract available

  69. KAWAMOTO S, Miyao M, Sakurai K, Kato K, et al
    Efficacy of 10% lidocaine gel for injection site pain associated with treprostinil in the treatment of pulmonary hypertension: a report of four cases.
    JA Clin Rep. 2025 Nov 29. doi: 10.1186/s40981-025-00834.
    PubMed    


  70. LIN C, Fu S, Li H, Zhang Y, et al
    RELM-beta Augmented Hypoxia-Induced Pulmonary Hypertension Through Interacting with GIPC1, OR1N1 and CLIC4.
    Cardiovasc Drugs Ther. 2025 Nov 29. doi: 10.1007/s10557-025-07816.
    PubMed    
    Abstract available

  71. CHEN P, Gong Q, Lu B, Zheng G, et al
    Surgical management of a patient with mirror-image dextrocardia with situs inversus, atrial septal defect, moderate tricuspid regurgitation, and moderate to severe pulmonary hypertension: a case report.
    J Cardiothorac Surg. 2025;20:445.
    PubMed    
    Abstract available

  72. AOYAMA BC, McGrath-Morrow SA, Collaco JM
    Bronchopulmonary Dysplasia Definitions As Predictors of Early Childhood Pulmonary Function.
    Pediatr Pulmonol. 2025;60:e71402.
    PubMed    
    Abstract available

  73. ZHENG Q, Zhao Z, Wang L, Yu C, et al
    Identification of endoplasmic reticulum stress-associated signatures of human pulmonary arterial hypertension: A bioinformatic analysis.
    Clin Exp Hypertens. 2025;47:2584570.
    PubMed    
    Abstract available

  74. BRAVO-VASQUEZ MJ, Cueto-Robledo G, Roldan-Valadez E, Navarro-Vergara DI, et al
    In situ pulmonary arterial thrombosis in pulmonary arterial hypertension: Diagnostic differentiation, imaging criteria, and management-A narrative review with an institutional case-series snapshot.
    Curr Probl Cardiol. 2026;51:103209.
    PubMed    
    Abstract available

  75. KIZILKAYA MH, Bilal MS, Gumus T, Celiker A, et al
    Inhaled iloprost and 2D phase-contrast cardiac MRI in pulmonary vascular reversibility: an adolescent case of anomalous right pulmonary artery from the ascending aorta.
    Cardiol Young. 2025;35:2353-2356.
    PubMed    
    Abstract available

  76. KULSHRESTHA S, Rai P
    Isolated absence of the right pulmonary artery in a neonate: a rare but critical incidental diagnosis.
    Cardiol Young. 2025;35:2383-2386.
    PubMed    
    Abstract available

  77. MO Y, Wang D, Bai Y
    Targeting PDGFR, EGFR, FGFR, and VEGFR: Key Receptor Tyrosine Kinases-Driven Metabolic Reprogramming in Pulmonary Arterial Hypertension.
    Med Res Rev. 2026;46:299-315.
    PubMed    
    Abstract available

  78. MO Y, Wang D, Deng Z, Zhao P, et al
    Endothelial SPRY1 deficiency associates with angiogenic-metabolic reprogramming in pulmonary arterial hypertension: a multi-omics analysis of bulk and single-cell transcriptomic profiles.
    Apoptosis. 2025;30.
    PubMed    
    Abstract available

  79. ZHU M, Li G, Li Y, Chen J, et al
    Circ_0005372 targets the miR-153-3p/ITGB3 axis to stimulate the PI3K/AKT signaling pathway to facilitate the occurrence and development of congenital heart disease and pulmonary arterial hypertension in children.
    Cardiovasc Pathol. 2026;80:107768.
    PubMed    
    Abstract available

  80. MENON DP, Frantz RP, Gochanour BR, Beck GJ, et al
    Ground-Glass Opacities in Pulmonary Arterial Hypertension-Results from the PVDOMICS Study.
    Ann Am Thorac Soc. 2025;22:1863-1873.
    PubMed    
    Abstract available

  81. ERSHED M, da Silva ABN, Felix de Farias Dos Santos AC, Heo D, et al
    Efficacy and safety of sotatercept in pulmonary arterial hypertension: a meta-analysis of randomized controlled trials.
    Expert Rev Respir Med. 2025;19:1273-1281.
    PubMed    
    Abstract available

  82. COGHLAN JG
    DETECTing pulmonary hypertension in patients with emphysema & systemic sclerosis: Can we? Should we?
    Rheumatology (Oxford). 2025 Dec 13:keaf671. doi: 10.1093.
    PubMed    


  83. KOOHI A, Rashidi F, Attaran D, Mirfeizi Z, et al
    Incidence of pulmonary hypertension in patients with Takayasu's arteritis: A transthoracic echocardiographic evaluation.
    Reumatol Clin (Engl Ed). 2025;21:501994.
    PubMed    
    Abstract available

  84. AHMED MA, Memon WUS, Ahmed OB
    Comment on: Nebulized nitroglycerin as an adjuvant drug in the management of persistent pulmonary hypertension of the newborn.
    Eur J Pediatr. 2025;185:13.
    PubMed    


  85. PATEL J, Doshi G
    Crosstalk between Ryanodine Receptor 2 Dysfunction and FK506-Binding Proteins in Pulmonary Hypertension.
    Cardiovasc Drugs Ther. 2025 Dec 13. doi: 10.1007/s10557-025-07809.
    PubMed    
    Abstract available

  86. MO Q, Wen X, Wang L, Cao W, et al
    Upregulated Calcium Sensing Receptor Mediates Pulmonary Venous Remodeling in Pulmonary Hypertension.
    Acta Physiol (Oxf). 2026;242:e70142.
    PubMed    
    Abstract available

  87. SINGH K, Kumar G K, Ali M, Choudhary R, et al
    Integrative blood profiling uncovers inflammatory network signatures in high-altitude pulmonary edema.
    Biosci Rep. 2025;45:BSR20253746.
    PubMed    
    Abstract available

  88. KIM NH, Delcroix M, Pepke-Zaba J
    To thin, or not too thin: questions of anticoagulation for pulmonary hypertension.
    Lancet Respir Med. 2025 Dec 8:S2213-2600(25)00373.
    PubMed    


  89. RUAN B, Chen M, Zhuang Q, Guan L, et al
    Chest Computed Tomography-Based Radiomics for the Diagnosis and Prognosis of Pulmonary Hypertension.
    J Am Heart Assoc. 2025 Dec 11:e043221. doi: 10.1161/JAHA.125.043221.
    PubMed    
    Abstract available

  90. NAYYAB I, Bashir H, Shahbaz H
    Incidental finding of antiphospholipid antibody syndrome in a patient with Cor Pulmonale: A case report.
    J Pak Med Assoc. 2025;75:1453-1455.
    PubMed    
    Abstract available

  91. MUSHTAQ MS, Gul H, Draz MU, Khan M, et al
    Comparison between clinical and immunological features of scleroderma with and without interstitial lung disease.
    J Pak Med Assoc. 2025;75:1445-1449.
    PubMed    
    Abstract available

  92. ALABSI AT, Yusuf KA, Aldoseri AS, Kanhosh SF, et al
    A Case of Right-Sided Heart Failure and Severe Pulmonary Hypertension Secondary to Partial Anomalous Pulmonary Venous Connection.
    Respirol Case Rep. 2025;13:e70438.
    PubMed    
    Abstract available

  93. ALI W, Ur Rab A, Shaikh A, Anil G, et al
    Palliative care in pulmonary hypertension: A systematic review and meta-analysis.
    World J Crit Care Med. 2025;14:110597.
    PubMed    
    Abstract available

  94. JENA N, Rrapo T, Pahi S, Pradhan J, et al
    Persistent Pulmonary Hypertension in Corrected Congenital Left Circumflex Artery to Coronary Sinus Fistula: A Case Report and Literature Review.
    Case Rep Cardiol. 2025;2025:6985938.
    PubMed    
    Abstract available


  95. Erratum: Integrative bioinformatics approach for identifying key genes and potential therapeutic targets in the concurrent manifestation of hypertrophic cardiomyopathy and pulmonary hypertension.
    J Thorac Dis. 2025;17:10589.
    PubMed    
    Abstract available

  96. TIAN R, Xu S, Liu C, Wang Y, et al
    Mesenchymal stem cell therapy for pulmonary hypertension: an update.
    Front Bioeng Biotechnol. 2025;13:1692396.
    PubMed    
    Abstract available

  97. VAN RENTERGHEM E, Legrand M, Lekane M, Roels E, et al
    Prognostic Value of Body Weight-Independent Tricuspid Annular Plane Systolic Excursion to Systolic Pulmonary Arterial Pressure Ratio in Canine Precapillary Pulmonary Hypertension: A Retrospective Study.
    Animals (Basel). 2025;15:3365.
    PubMed    
    Abstract available

  98. GONG C, Lan X, Xie Y, Wu X, et al
    Overexpression of PRDX2 alleviates chronic thromboembolic pulmonary hypertension by modulating inflammation and mitophagy.
    Sci Rep. 2025 Dec 10. doi: 10.1038/s41598-025-31063.
    PubMed    
    Abstract available

  99. SHOMURA T, Wada Y, Goto N, Suzuki Y, et al
    Impact of bendopnea on indicators of pulmonary hypertension, health-related quality of life, and pulmonary function in patients with chronic obstructive pulmonary disease.
    Respir Investig. 2025;64:101346.
    PubMed    
    Abstract available

  100. SALIBE-FILHO W, Vieira TM, Leonidas Alves-Junior J, Nascimento YPP, et al
    Upfront combination therapy with sildenafil and ambrisentan in patients with chronic thromboembolic pulmonary hypertension.
    J Bras Pneumol. 2025;51:e20250056.
    PubMed    
    Abstract available

  101. HELD M, Pausch C, Huscher D, Pittrow D, et al
    Survival in patients with chronic thromboembolic pulmonary hypertension treated with riociguat versus other medications: a COMPERA analysis.
    ERJ Open Res. 2025;11:00230-2025.
    PubMed    
    Abstract available

  102. DELCROIX M, Lang IM, D'Armini AM, Fadel E, et al
    Long-term effects of medical treatment in patients with chronic thromboembolic pulmonary hypertension.
    ERJ Open Res. 2025;11:00769-2025.
    PubMed    
    Abstract available

  103. LI Y, Bin N, Zhou J, Jiang L, et al
    Trends and projections of the global burden of pulmonary arterial hypertension (1990-2050): An observational trend study.
    Medicine (Baltimore). 2025;104:e46448.
    PubMed    
    Abstract available

  104. FADEL NB, Almoli E, de Nanassy J, Mashally S, et al
    New Insights: P.I.G in Preterm Infants With Isolated PDA and Severe Pulmonary Hypertension.
    Case Rep Pediatr. 2025;2025:6268296.
    PubMed    
    Abstract available

  105. QI LQ, Xue ZF, Liu XS
    [Research advances on mitochondria-associated endoplasmic reticulum membrane in pulmonary hypertension].
    Zhonghua Jie He He Hu Xi Za Zhi. 2025;48:1196-1202.
    PubMed    
    Abstract available

  106. LEE I, Joh JS, Lee JY, Kim J, et al
    Clinical outcome prediction by high-resolution computed tomography and echocardiography assessment of pulmonary hypertension in patients with bronchiectasis.
    Tuberc Respir Dis (Seoul). 2025 Dec 9. doi: 10.4046/trd.2025.0067.
    PubMed    
    Abstract available

  107. KRAMER T, Kramer M, Hagist C, Spinler S, et al
    Artificial intelligence in pulmonary hypertension: a systematic review.
    Eur J Med Res. 2025;30:1225.
    PubMed    
    Abstract available

  108. COSTA SFF, Leite LB, Soares LL, Dos Lucio Generoso SC, et al
    Resistance exercise training attenuates skeletal muscle atrophy in experimental pulmonary arterial hypertension.
    Pflugers Arch. 2025;478:3.
    PubMed    
    Abstract available

  109. SHIMIZU D, Goda A, Tashiro S, Tobita K, et al
    Association of bioelectrical impedance phase angle with exercise tolerance in patients with chronic thromboembolic pulmonary hypertension.
    Sci Rep. 2025 Dec 8. doi: 10.1038/s41598-025-27925.
    PubMed    


  110. BERRA G, Genecand L, Juillet A, Deux JF, et al
    Reversible pulmonary hypertension in a patient diagnosed with scurvy.
    BMJ Case Rep. 2025;18:e266143.
    PubMed    
    Abstract available

  111. PLAZAK W, Bernhardt AM
    Pulmonary hypertension in heart failure patients in the modern era of mechanical circulatory support.
    Kardiol Pol. 2025;83:1259-1267.
    PubMed    
    Abstract available

  112. ABOFREKHA B, Jdaidani J, Shadi M, Sanayeh EB, et al
    Improvement in Right Ventricular Function and Pulmonary Pressures in Patients With Severe Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction Treated With Sacubitril-Valsartan.
    Pulm Circ. 2025;15:e70217.
    PubMed    
    Abstract available

  113. ZHANG Y, Liu C, Zhou J, Li W, et al
    Iron status mediates the causal effects of high-altitude adaptation signals in the HIF-PHD axis on pulmonary vascular and right-heart outcomes.
    Clin Exp Hypertens. 2025;47:2595152.
    PubMed    
    Abstract available

  114. BAEZ-FERRER N, Abril-Pla M, Al-Hayani-Al-Hantoosh AW, Avanzas P, et al
    Prognostic significance of combined pulmonary hypertension in mitral regurgitation surgery.
    Rev Esp Cardiol (Engl Ed). 2025 Dec 4:S1885-5857(25)00347.
    PubMed    


  115. LONG C, Lin M, Wang W, Liu Y, et al
    RNA-seq and ChIP-seq reveal microplastics induce endothelial-mesenchymal transition via HK2-mediated histone lactylation in pulmonary hypertension.
    Vascul Pharmacol. 2025;162:107571.
    PubMed    
    Abstract available

  116. LAMBERTI K, Grinstein J
    Practical Application of Pressure-Volume Loops and Cardiac Energetics to Improve Care Delivery in Pulmonary Hypertension: Have We Finally Found the "RIGHT" Toolbox?
    JACC Heart Fail. 2025 Dec 5:102781. doi: 10.1016/j.jchf.2025.102781.
    PubMed    


  117. ESTRADA RA, Baher H, Andrade L, Zabelny K, et al
    Vaccination utilization in patients with pulmonary hypertension.
    Respir Med. 2025;251:108549.
    PubMed    
    Abstract available

  118. AGUADO B, Ruffenach G, Lacoste-Palasset T, Gorlach A, et al
    Use of SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors in Pulmonary Hypertension.
    Circ Heart Fail. 2025 Dec 5:e013481. doi: 10.1161/CIRCHEARTFAILURE.125.013481.
    PubMed    
    Abstract available

  119. AHMED F, Haider F, Arham M, Dad A, et al
    Comparative diagnostic accuracy of artificial intelligence-derived risk stratification versus conventional risk stratification methods in pulmonary hypertension patients: a systematic review and meta-analysis.
    Front Artif Intell. 2025;8:1692829.
    PubMed    
    Abstract available

  120. WANG K, Li X, Song S, Li H, et al
    Quantifying Right Ventricular Fibrosis Burden in CTEPH via FAPI SPECT/CT: Correlation with Echocardiographic Parameters and BPA Response.
    J Nucl Cardiol. 2025 Nov 20:102565. doi: 10.1016/j.nuclcard.2025.102565.
    PubMed    
    Abstract available

  121. YIN C, Deng C, Crespi CM, Bar S, et al
    The relation between Down syndrome and co-occurring conditions in children and young adults: A population-based cohort in Denmark, 1977-2016.
    Res Dev Disabil. 2025;167:105167.
    PubMed    
    Abstract available

  122. CHATURVEDI G, Dubey N, Panchbhai P, Singh S, et al
    Mitochondrial-ER crosstalk: An emerging mechanism in the pathophysiology of pulmonary arterial hypertension.
    Mitochondrion. 2026;86:102094.
    PubMed    
    Abstract available

  123. ALI MS, Elhabak M, Ibrahim SS, Elmowafy E, et al
    Breath-activated nanomedicine: Ambrisentan-loaded chitosomes for pulmonary arterial hypertension.
    Int J Pharm. 2026;687:126370.
    PubMed    
    Abstract available

  124. POPE J
    Novel therapies in SSc.
    Best Pract Res Clin Rheumatol. 2025;39:102104.
    PubMed    
    Abstract available

  125. HATA A, Gur B, Kalra J, Prabhakar A, et al
    Pulmonary veno-occlusive disease: Insights from animal models.
    Vascul Pharmacol. 2025;161:107547.
    PubMed    
    Abstract available

  126. EGBE AC, Reddy YNV, Pellikka PA, Borlaug BA, et al
    Impaired Pulmonary Vascular Reserve in Adults with Repaired Coarctation of Aorta: Prevalence, Correlates, and Association with Disease Severity.
    J Am Soc Echocardiogr. 2025;38:1179-1188.
    PubMed    
    Abstract available

  127. SHALABI L, Tabassum S, Al Zoubi BM, Taha HI, et al
    Efficacy and safety of sotatercept in pulmonary arterial hypertension: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis.
    Naunyn Schmiedebergs Arch Pharmacol. 2025;398:16767-16778.
    PubMed    
    Abstract available

  128. RUSCITTI P, Vitale A, Di Cola I, Caggiano V, et al
    The clinical assessment of lung involvement in patients with Still's disease, results from the multicentre international AIDA Network Still's Disease Registry.
    Rheumatology (Oxford). 2025;64.
    PubMed    
    Abstract available

  129. MAGHSOUDI S, Bhatia V, Hinton M, Singh N, et al
    Adenylyl Cyclase Isoform 6 in the Pulmonary Artery Is Inhibited by Hypoxia via Cysteine Nitrosylation.
    Am J Respir Cell Mol Biol. 2025;72:82-96.
    PubMed    
    Abstract available

  130. CRAWFORD R, McLeod L, Yarr S, Morrison R, et al
    Initial Evaluation of the Pulmonary Hypertension Functional Classification Self-Report (PH-FC-SR) Measurement Properties: A Patient-Focused Measure.
    Chest. 2025 Nov 27:S0012-3692(25)05804-0. doi: 10.1016/j.chest.2025.
    PubMed    
    Abstract available

  131. KHAN SL, Paoli CJ, Kime N, Williams K, et al
    Treatment patterns in incident pulmonary hypertension patients: real-world data from the Pulmonary Hypertension Association Registry.
    Chest. 2025 Dec 8:S0012-3692(25)05817-9. doi: 10.1016/j.chest.2025.
    PubMed    
    Abstract available

  132. WOODCOCK CC, Maroli G, Kim H, Tai YY, et al
    Endothelial ADAR1 Deficit Induces the NOCT-IRF7 Axis in Pulmonary Hypertension.
    Circ Res. 2025 Dec 4. doi: 10.1161/CIRCRESAHA.125.326277.
    PubMed    
    Abstract available

  133. MESERVEY A, Feng R, Kawut SM, Moutchia J, et al
    Reply to: Enhancing methodological rigour in meta-analyses of renal dysfunction and outcomes in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Eur Respir J. 2025;66:2501579.
    PubMed    


  134. DONG F, Lin H, Han Y
    Enhancing methodological rigour in meta-analyses of renal dysfunction and outcomes in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Eur Respir J. 2025;66:2501196.
    PubMed    
    Abstract available

  135. GRYNBLAT J, Farges M, Magro P, Savale L, et al
    Pulmonary hypertension in patients with Noonan syndrome.
    Eur Respir J. 2025 Dec 11:2501796. doi: 10.1183/13993003.01796-2025.
    PubMed    
    Abstract available

  136. MULLER J, Mayer L, Schneider SR, Bauer M, et al
    Pulmonary haemodynamics and right heart function during exercise at high versus low altitude in patients with pulmonary vascular disease: a randomised crossover trial.
    Heart. 2025;112:28-36.
    PubMed    
    Abstract available

  137. JENKINS DP, Cerovic S, Csonka D, Ghofrani HA, et al
    Results of the MACiTEPH study of macitentan for the treatment of inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension.
    J Heart Lung Transplant. 2025 Nov 24:S1053-2498(25)02402.
    PubMed    
    Abstract available

  138. RICH JD
    Elevated PVR: When Pulmonary Hypertension Becomes Disease, Not Just Pressure?
    J Heart Lung Transplant. 2025 Nov 21:S1053-2498(25)02335.
    PubMed    


  139. MIARD C, Genty T, Louvain-Quintard V, Rezaiguia-Delclaux S, et al
    High Antiphospholipid Antibody Titers and Outcomes of Pulmonary Endarterectomy: A Single-Center Retrospective Observational Cohort Study.
    J Heart Lung Transplant. 2025;44:1996-2007.
    PubMed    
    Abstract available

  140. GHANI H, Pepke-Zaba J
    Old clots, new questions - the anticoagulation saga continues in chronic thromboembolic pulmonary hypertension.
    J Heart Lung Transplant. 2025 Nov 28:S1053-2498(25)02417.
    PubMed    


  141. BALASUBRAMANIAN A, Hemnes AR, Brittain EL, Annis J, et al
    Disproportionate impairment in diffusing capacity predicts pulmonary hypertension with an elevated pulmonary vascular resistance in COPD.
    Thorax. 2025 Nov 27:thorax-2025-223921. doi: 10.1136/thorax-2025-223921.
    PubMed    
    Abstract available

  142. TAYLOR JC, Knowlton KU, Wilson TC, Dodson MW, et al
    Recurrent right atrial myxoma presenting as pulmonary hypertension and peripheral pulmonary artery aneurysms.
    Thorax. 2025 Dec 10:thorax-2025-223625. doi: 10.1136/thorax-2025-223625.
    PubMed    



Thank you for your interest in scientific medicine.


AMEDEO Pulmonary Hypertension is free of charge.


;